^
    19d
    Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=51, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • Epidaza (chidamide) • lisaftoclax (APG-2575)
    21d
    Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients (clinicaltrials.gov)
    P2/3, N=60, Not yet recruiting, The Affiliated People's Hospital of Ningbo University
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • lisaftoclax (APG-2575)
    1m
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=0, Withdrawn, M.D. Anderson Cancer Center | N=24 --> 0 | Trial completion date: Jun 2032 --> Apr 2026 | Initiation date: Aug 2026 --> Apr 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2030 --> Apr 2026
    Enrollment change • Trial completion date • Trial initiation date • Trial withdrawal • Trial primary completion date
    |
    clonoSEQ®
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    1m
    APG-2575-CN-001: A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, Ascentage Pharma Group Inc. | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    lisaftoclax (APG-2575)
    1m
    APG2575AC101: Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML (clinicaltrials.gov)
    P1/2, N=682, Recruiting, Ascentage Pharma Group Inc. | N=458 --> 682
    Enrollment change
    |
    azacitidine • Nailike (olverembatinib) • lisaftoclax (APG-2575) • Synribo (omacetaxine mepesuccinate)
    1m
    Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • Epidaza (chidamide) • lisaftoclax (APG-2575)
    2ms
    The Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients with Indolent Lymphoma (ChiCTR2600121485)
    P4, N=75, Henan Cancer Hospital; Henan Cancer Hospital
    New P4 trial
    |
    Breyanzi (lisocabtagene maraleucel) • lisaftoclax (APG-2575)
    2ms
    A phase II clinical study evaluating azacitidine combined with lisaftoclaxl in newly diagnosed patients with higher-risk MDS (ChiCTR2600118868)
    P2, N=53, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    azacitidine • lisaftoclax (APG-2575)
    2ms
    APG2575CC201: Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (clinicaltrials.gov)
    P2, N=75, Recruiting, Ascentage Pharma Group Inc. | Trial completion date: Dec 2024 --> Dec 2027 | Trial primary completion date: Sep 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    lisaftoclax (APG-2575)
    3ms
    Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Indolent Lymphoma (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    lisaftoclax (APG-2575)
    4ms
    A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=24, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    clonoSEQ®
    |
    cytarabine • pelcitoclax (APG-1252) • lisaftoclax (APG-2575) • fludarabine IV
    4ms
    Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=122, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • lisaftoclax (APG-2575) • Polivy (polatuzumab vedotin-piiq)